Acuta Capital Partners’s Insmed INSM Stock Holding History

Acuta Capital Partners’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-50,000	Closed	-$858K	–	71
2017 Q2	$858K	Buy	+50,000	New	+$854K	0.24%	46

Other funds holding INSM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Acuta Capital Partners's INSM Position: Q1 2026 in Review

Acuta Capital Partners sold out of Insmed (INSM) in Q1 2026, closing a stake of 25,878 shares — an estimated $4.5M sold.

Acuta Capital Partners first reported a position in INSM in Q4 2014 and held it in 17 quarters. The position peaked at $11.1M in Q2 2019. 670 funds tracked by Wall St. Rank hold INSM as of Q1 2026.

Acuta Capital Partners reported no remaining Insmed position as of Q1 2026 after selling out during the quarter.
Acuta Capital Partners sold 25,878 Insmed shares in Q1 2026, an estimated $4.5M.
Acuta Capital Partners first reported a position in Insmed in Q4 2014 and held it in 17 quarters.
Acuta Capital Partners's Insmed position peaked at $11.1M in Q2 2019.
670 funds tracked by Wall St. Rank held Insmed as of Q1 2026.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.